Next Phase Newsletter

A pharmaceutical company that specializes in Liver Disease, CNS, and Diabetes is actively searching for promising therapeutic candidates under development around the world to invest in or incorporate into its pipeline. The firm is flexible in terms of the structure, and has the ability to invest, in-license, acquire, and co-develop products. If investing in a company, the firm is most interested in private companies, though does look at public companies. The firm will invest in Series A/B companies or assets, and will typically invest between $1M-$5M per allocation depending on the opportunity. The firm is interested in world wide/major territories such as the US, EU, APAC, and East Asia.

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is most interested in therapies targeting liver disease, though is indication agnostic with added interest in neurology, hepatology, oncology, and gastroenterology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan disease. The firm will look at both small molecules and biologics and will consider both NCE or NCE-like molecules, as well as re-positioning molecule to a new indication. The firm is not in OTC drugs. The company prefers assets in phase I, II, IND-ready, or preclinical with some in-vivo data. However, the company will also look at assets in phase III and NDA stage.

The firm will consider partnership opportunities from around the world and has no specific management team or distribution right requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital fund is currently investing from its roughly $70 million fund closed in 2014. The initial investment size is highly variable although the firm is looking to provide up to $10+ million over the lifetime of the investment. The firm generally provides capital in the form of equity although they also have experience in working with convertible notes. The firm is interested in companies located in North America or Asia, with a special interest in regions outside of traditional biotech hubs. The firm’s primary focus is on private companies while public investments are also made selectively.

The firm is currently interested in companies developing Therapeutics, Diagnostics, Medical Devices, and R&D Services Companies. The firm is entirely opportunistic in terms of subsector and indication. In terms of phase of development, the firm is looking for companies with lead assets in the preclinical stage to companies that already have products on the market. The firm will consider companies in various stages on a case by case basis including seed financing.

The firm views the management team as one of the most important variables in selecting a potential investment. The firm looks for highly experienced and trustworthy management teams. The firm is highly interest in US based companies that are looking to expand into Asian markets or vice versa as member of the fund can add much value in these situations with their vast Asian network. However this US-Asia business development angle is not a criteria or requirement for the firm’s investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was established in 2000 and is based in the central US is currently in the process of raising its 2nd fund targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm makes as many as 12 allocations per year and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in Sectors of Telemedicine, Healthcare IT, Pathology, Diagnostics, Bioinformatics, Medical Devices and more recently Vaccines. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to working with them. The firm looks to take a board seat following investment. In addition to capital the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A growth stage venture firm backed by a sole investor manages a portfolio of companies that spans across a variety of industries; about a third of the portfolio is in the healthcare medtech space. The firm has a specific competitive advantage as a long lifetime fund with the ability to invest throughout the lifetime of a company. The firm currently manages a $540M fund and typically invests in series A/B/C rounds with a preference towards series B/C technology at the growth equity stage. The firm typically invests globally at $10M-$30M per company.

The firm has particular interest in innovative products that can apply to other sectors. The firm has particular interest in medical technology—including biodiscovery platforms, next-generation surgical treatments and devices, biomaterials, dental devices, imaging, and regenerative medicine—though is sector agnostic. The firm is also open to therapeutic and diagnostic technology with innovative pathways, as well as both 510K and PMA devices with clear regulatory pathways (FDA approval/benchmarks). The firm typically invests in preclinical/in development technology, though is open to technology in all phases of development. The firm is indication agnostic and has particular interest in pursuing innovative technology in areas where there is not a lot of trending interest with the ability to be the first in the market.

The firm prefers companies with considerable insight and experience in the space. The firm highlights strong, animated founders with transformational vision and technology that have the potential to produce significant revenue traction. The firm supports what is best for the company, whether it be taking a board seat after an investment or helping fill the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A medical technology venture firm founded in 2013 and based in the Northeast USA makes equity investments in early stage companies developing products to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $15-20 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities across the world.

The firm focuses three market segments that support knowledge-generating precision medicine: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) guided and personalized minimally invasive therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Asia-based corporate venture capital fund with a US office in California seeks to co-invest up to $3 million in Series B or C rounds. The corporate VC does not have a defined fund or budget, though typically invests a total of $10M-$20M per year, including in follow-on investments. The fund is currently seeking 2-3 new investments within the next year. The fund seeks opportunities in the U.S., Asia, Europe and Israel.

The fund has two focus areas in the life sciences; firstly, medical device technologies that have strategic relevance to the parent firm’s semiconductor business with a focus on diagnostic instrumentation and nano fabrication technology; and secondly, innovations in stem cell ancillary technology. The fund does not invest in stem cell therapies or treatments, but will look at biotech R&D innovations in the stem cell field that cultivate, study, and analyze stem cell lines. The fund is particularly interested in companies that can benefit from the parent firm’s strategic capabilities, such as companies that will need silicon nanofabrication technology. The fund is currently looking at all classes of medical device technologies, including sensor technology.

The fund typically invests in pre-revenue companies, but prefers that companies have a completed prototype and proof of concept data. The fund only invests in opportunities where the parent firm’s industry expertise is relevant, and typically provides their portfolio companies with business development and marketing support in addition to capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based early stage fund focused on angel investment and incubation in the healthcare field is currently investing from its RMB 200 M fund (USD 30 M) closed in 2015, backed by several Chinese healthcare companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com